rilzabrutinib (PRN1008)
oral reversible covalent BTK inhibitor in Ph. III for immune thrombocytopenia from structure-based drug design + opt. J. Med. Chem., March 18, 2022 Principia Biopharma (Sanofi), So. San Francisco, CA
Molecules of the Month - March 2022
Molecules of the Month
- rilzabrutinib (PRN1008)
- INE963
- ulevostinag (MK-1454)
- compound 24
- compound 10
- etavopivat
- BMS-986176/LX-9211
- branaplam
- MAK683
- HR1405-01